Breast Cancer Clinical Trial

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Summary

This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histological or cytological diagnosis of triple negative breast cancer (TNBC) with evidence of a) metastatic or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent.
Availability of an original diagnostic tumor tissue or the most recent metastatic tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for Notch receptors genomic profiling

Exclusion Criteria:

Known brain metastases.
Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT02299635

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 33 Locations for this study

See Locations Near You

Stanford Cancer Institute
Stanford California, 94305, United States
Stanford Hospital and Clinics
Stanford California, 94305, United States
Stanford Women's Cancer Center
Stanford California, 94305, United States
The University of Chicago Medical Center
Chicago Illinois, 60637, United States
University of Chicago Medical Center
Chicago Illinois, 60637, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox Illinois, 60451, United States
Midwestern Regional Medical Center
Zion Illinois, 60099, United States
Brigham and Women's Hospital (BWH)
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute (DFCI)
Boston Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge New Jersey, 07920, United States
The Valley Hospital - Luckow Pavilion
Paramus New Jersey, 07652, United States
Valley Medical Group
Paramus New Jersey, 07652, United States
Valley Medical Group
Westwood New Jersey, 07675, United States
Memorial Sloan Kettering Cancer Center Commack
Commack New York, 11725, United States
Memorial Sloan Kettering Cancer Center West Harrison
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Memorial Sloan Kettering Cancer Center Rockville Centre
Rockville Centre New York, 11570, United States
Memorial Sloan Kettering Cancer Center Sleepy Hollow
Sleepy Hollow New York, 10591, United States
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Intezet
Debrecen , 4032, Hungary
Presidio Ospedaliero Vito Fazzi
Lecce , 73100, Italy
Istitutio Europeo di Oncologia
Milan , 20141, Italy
Vesalius
Krakow , 31108, Poland
Vesalius Poradnia Onkologiczna i Hematologiczna
Krakow , 31216, Poland
Szpital Kliniczny Przemienienia Panskiego, Uniwersutetu Medycznego im. Karola Marcinkowskiego
Poznan , 60-56, Poland
Complejo Hospitalario Universitario A Coruna (Hospital Teresa Herrera)
A Coruna , 15006, Spain
Hospital Universitari Vall d'Hebron
Barcelona , 08035, Spain
Hospital Clinic de Barcelona
Barcelona , 08036, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona , 08041, Spain
Instituto Catalan de Oncologia de L'Hospitalet de Llobregat (ICO)
Barcelona , 08908, Spain
Hospital General Universitario Gregorio Maranon
Madrid , 28007, Spain
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain
Hospital Universitario Virgen del Rocio
Sevilla , 41013, Spain
Hospital Clínico Universitario de Valencia
Valencia , 46010, Spain
Beatson West of Scotland Cancer Centre
Glasgow Scotland, G12 0, United Kingdom
Ross Hall Hospital
Glasgow Scotland, G52 3, United Kingdom
The Royal Marsden NHS Foundation Trust
London , SW3 6, United Kingdom
The Royal Marsden NHS Foundation Trust
Surrey , SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT02299635

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider